Eagle Biologics, Inc.

Alyssa M Larson

Robert Samuel Langer

Alexander M Klibanov

Kevin Thomas Love

Alan Crane

Alisha K Weight

Robert S Langer, Jr

Robert S Langer

Kevin Love

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.

Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC)

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.

Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP)

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of polysaccharides and nucleic acids have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight polysaccharides and nucleic acids, and viscosity-lowering agents.

Polysaccharide and nucleic acid formulations containing viscosity-lowering agents

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.

Liquid Protein Formulations Containing Thiamine

Liquid protein formulations containing 4-(3-butyl-1-imidazolio)-1-butane sulfonate (BIM)

Liquid protein formulations containing thiamine pyrophosphate (TPP)

Liquid protein formulations containing cimetidine

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering water soluble organic dyes.

Liquid pharmaceutical formulations for injection comprising yellow 5 or orange G and uses thereof

Liquid pharmaceutical formulations for injection comprising procaine and uses thereof

Liquid pharmaceutical formulations for injection comprising thiamine pyrophosphate 1-(3-aminopropyl)-2-methyl-1H-imidazole and uses thereof

Liquid protein formulations for injection comprising 1-butyl-3-methylimidazolium methanesulfonate and uses thereof

Growing community of inventors

Dana Point, CA, United States of America

Alyssa M Larson